Skip to main content

Posts

Showing posts with the label Recursion Pharma

Featured Post

Market Daily Report: Bursa Malaysia Ends Nearly Flat As Construction Stocks Attract Buying

 KUALA LUMPUR, Sept 8 (Bernama) -- Bursa Malaysia closed almost flat on Tuesday as buying interest rotated away from index heavyweights towards smaller-cap construction stocks, with sentiment affected by geopolitical uncertainty, said an analyst. At 5 pm, the FTSE Bursa Malaysia KLCI (FBM KLCI) eased 0.39 of a point to 1,714.40 from Monday’s close of 1,714.79. The benchmark index opened 1.65 points lower at 1,713.14 and moved between 1,710.44 and 1,714.50 throughout the trading session. The broader market was almost evenly balanced, with decliners leading gainers 548 to 546, while 598 counters were unchanged, 1,107 were untraded and 25 were suspended. Turnover expanded to 4.13 billion units valued at RM3.14 billion from 3.60 billion units valued at RM2.45 billion on Monday.

Why Is Recursion Pharma (RXRX) Soaring? AI-Designed Cancer Drug Sparks Hope & Investor Excitement

Stock up 9.6% — here's why investors are buzzing Breakthrough Spotlight: $Recursion Pharmaceuticals (RXRX.US)$ surged Monday after a  WIRED article  spotlighted  REC-3565 , an AI-designed MALT1 inhibitor drug showing  promising early signs in fighting blood cancer . Developed using Recursion’s cutting-edge AI platform, this molecule is something “ humans couldn’t have designed ” through traditional means, according to Peter Ray, Senior Director of Medicinal Chemistry. What Makes This Different? Only 136 molecules  were tested to develop REC-617, thanks to AI—vs. thousands in conventional drug discovery REC-3565  is now in  Phase 1 trials  for relapsed leukemia and B-cell lymphoma Ray believes this is just the start: “Each drug we develop makes the next 10 even better.” Why Investors Care: AI speeds up R&D and slashes costs Real-life patient in REC-617 trial showed  miraculous recovery signs Market sees Recursion leading the next-gen ...